A detailed history of Rhumbline Advisers transactions in Biote Corp. stock. As of the latest transaction made, Rhumbline Advisers holds 33,768 shares of BTMD stock, worth $205,984. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,768
Previous 28,225 19.64%
Holding current value
$205,984
Previous $210,000 10.48%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.33 - $8.36 $29,544 - $46,339
5,543 Added 19.64%
33,768 $188,000
Q2 2024

Aug 01, 2024

BUY
$5.44 - $7.47 $78,357 - $107,597
14,404 Added 104.22%
28,225 $210,000
Q1 2024

May 09, 2024

SELL
$3.79 - $6.91 $981 - $1,789
-259 Reduced 1.84%
13,821 $80,000
Q3 2023

Nov 09, 2023

BUY
$4.73 - $7.83 $5,382 - $8,910
1,138 Added 8.79%
14,080 $72,000
Q2 2023

Aug 08, 2023

BUY
$5.27 - $6.9 $68,204 - $89,299
12,942 New
12,942 $87,000

Others Institutions Holding BTMD

About biote Corp.


  • Ticker BTMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 7,574,270
  • Market Cap $46.2M
  • Description
  • biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biot...
More about BTMD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.